Skip to main content
SpringerLink
Log in
Book cover

Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease pp 39–71Cite as

Glycoprotein IIb/IIIa in Platelet Aggregation and Acute Arterial Thrombosis

  • Chapter

  • 109 Accesses

Part of the book series: Contemporary Cardiology ((CONCARD))

Abstract

Glycoprotein (GP) IIb/IIIa antagonists have been shown to therapeutically regulate platelet function to prevent, for example, the thrombotic complications associated with coronary artery disease (1). Moreover, it is now suggested that the modulation of GPIIb/IIIa affects not only platelet aggregation and thrombosis, but also inflammation, which might ultimately result in a reduction of recurrent thrombotic events. Three main reasons explain why GPIIb/IIIa (αIIb β3 integrin) (2) is an ideal platelet target for the treatment of acute -IIbbarterial thrombosis and why the development of GPIIb/IIIa antagonists has been successful. First, GPIIb/IIIa is on the “final common pathway” (3) mediating platelet aggregation, a process central to acute arterial thrombosis, irrespective of the agonist used to induce platelet activation. Second, GPIIb/IIIa is a platelet-specific glycoprotein, the most abundant protein on the platelet surface. Third, the dynamic nature of GPIIb/IIIa allows it to affect a variety of platelet responses, therefore allowing GPIIb/IIIa antagonists to modulate a variety of platelet functions including those involved in coagulation, inflammation, fibrinolysis, and vascular cell proliferation.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Lincoff AM, Califf RM, Topol EJ. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease. J Am Coll Cardiol 2000;35:1103–1115.

    Article  PubMed  CAS  Google Scholar 

  2. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992;69:11–25.

    Article  PubMed  CAS  Google Scholar 

  3. Coller BS. Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy. Circulation 1995;92: 2373–2380.

    Article  PubMed  CAS  Google Scholar 

  4. Law DA, et al. Genetic and pharmacological analyses of Syk function in alphaIIbbeta3 signaling in platelets. Blood 1999;93:2645–2652.

    PubMed  CAS  Google Scholar 

  5. Phillips DR, et al. Integrin tyrosine phosphorylation in platelet signaling. Curr Opin Cell Biol 2001;13: 546–554.

    Article  PubMed  CAS  Google Scholar 

  6. Andre P, et al. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med 2002;8:247–252.

    Article  PubMed  CAS  Google Scholar 

  7. Wagner CL, et al. Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood 1996;88:907–914.

    PubMed  CAS  Google Scholar 

  8. Youssefian T, et al. Platelet and megakaryocyte dense granules contain glycoproteins Ib and IIb-IIIa. Blood 1997;89:4047–4057.

    PubMed  CAS  Google Scholar 

  9. Shiba E, et al. Antibody-detectable changes in fibrinogen adsorption affecting platelet activation on polymer surfaces. Am J Physiol 1991;260:C965–C974.

    PubMed  CAS  Google Scholar 

  10. Gralnick HR, et al. Endogenous platelet fibrinogen surface expression on activated platelets. J Lab Clin Med 1991;118:604–613.

    PubMed  CAS  Google Scholar 

  11. Legrand C, Dubernard V, Nurden AT. Studies on the mechanism of expression of secreted fibrinogen on the surface of activated human platelets. Blood 1989;73:1226–1234.

    PubMed  CAS  Google Scholar 

  12. Wencel-Drake JD, et al. Localization of internal pools of membrane glycoproteins involved in platelet adhesive responses. Am J Pathol 1986;124:324–334.

    PubMed  CAS  Google Scholar 

  13. Handagama P, et al. Endocytosis of fibrinogen into megakaryocyte and platelet alpha-granules is mediated by alpha IIb beta 3 (glycoprotein IIb-IIIa). Blood 1993;82:135–138.

    PubMed  CAS  Google Scholar 

  14. Wencel-Drake JD, et al. Arg-Gly-Asp-dependent occupancy of GPIIb/IIIa by applaggin: evidence for internalization and cycling of a platelet integrin. Blood 1993;81:62–69.

    PubMed  CAS  Google Scholar 

  15. Pike NB, Lumley P. Uptake of a fibrinogen receptor antagonist by human platelets appears dependent upon GPIIb/IIIa. Thromb Haemost 1995;73:1195.

    Google Scholar 

  16. Nurden P, et al. Labeling of the internal pool of GP IIb-IIIa in platelets by c7E3 Fab fragments (abciximab): flow and endocytic mechanisms contribute to the transport. Blood 1999;93:1622–1633.

    PubMed  CAS  Google Scholar 

  17. Woods VL Jr, Wolff LE, Keller DM. Resting platelets contain a substantial centrally located pool of glycoprotein IIb-IIIa complex which may be accessible to some but not other extracellular proteins. J Biol Chem 1986;61:15,242–15,251.

    PubMed  CAS  Google Scholar 

  18. Kleiman NS, et al. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors. J Am Coll Cardiol 1995;26:1665–1671.

    Article  PubMed  CAS  Google Scholar 

  19. Cook JJ, et al. Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, along-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongation. J Pharmacol Exp Ther 1997;281:677–689.

    PubMed  CAS  Google Scholar 

  20. Stenberg PE, et al. A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. J Cell Biol 1985;101:880–886.

    Article  PubMed  CAS  Google Scholar 

  21. Nurden AT, et al. Markers of platelet activation in coronary heart disease patients. Eur J Clin Invest 1994;24(Suppl 1):42–45.

    PubMed  Google Scholar 

  22. Parise LV, et al. Evidence for novel binding sites on the platelet glycoprotein IIb and IIIa subunits and immobilized fibrinogen. Biochem J 1993;289:445–451.

    PubMed  CAS  Google Scholar 

  23. Ni H, et al. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest 2000;106:385–392.

    Article  PubMed  CAS  Google Scholar 

  24. Angelillo-Scherrer A, et al. Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. Nat Med 2001;7:215–221.

    Article  PubMed  CAS  Google Scholar 

  25. Konstantinides S, et al. Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J Clin Invest 2001;108:1533–1540.

    PubMed  CAS  Google Scholar 

  26. Nakata M, et al. Leptin promotes aggregation of human platelets via the long form of its receptor. Diabetes 1999;48:426–429.

    Article  PubMed  CAS  Google Scholar 

  27. Dale GL, et al. Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface. Nature 2002;415:175–179.

    Article  PubMed  CAS  Google Scholar 

  28. Weisel JW, et al. Examination of the platelet membrane glycoprotein IIb-IIIa complex and its interaction with fibrinogen and other ligands by electron microscopy. J Biol Chem 1992;267:16,637–16,643.

    CAS  Google Scholar 

  29. Ulmer TS, et al. NMR analysis of structure and dynamics of the cytosolic tails of integrin alpha IIb beta 3 in aqueous solution. Biochemistry 2001;40:7498–7508.

    Article  PubMed  CAS  Google Scholar 

  30. Phillips DR, et al. The platelet membrane glycoprotein lIb-IIIa complex. Blood 1988;71:831–843.

    PubMed  CAS  Google Scholar 

  31. Farrell DH, et al. Role of fibrinogen alpha and gamma chain sites in platelet aggregation. Proc Natl Acad Sci USA 1992;89:10,729–10,732.

    Article  CAS  Google Scholar 

  32. Farrell DH, Thiagarajan, P. Binding of recombinant fibrinogen mutants to platelets. J Biol Chem 1994; 269:226–231.

    PubMed  CAS  Google Scholar 

  33. Kloczewiak M, et al. Platelet receptor recognition site on human fibrinogen. Synthesis and structurefunction relationship of peptides corresponding to the carboxy-terminal segment of the gamma chain. Biochemistry 1984;23:1767–1774.

    Article  PubMed  CAS  Google Scholar 

  34. Abrams CS, et al. Anti-idiotypic antibodies against an antibody to the platelet glycoprotein (GP) IIb-IIIa complex mimic GP IIb-IIIa by recognizing fibrinogen. J Biol Chem 1992;267:2775–2785.

    PubMed  CAS  Google Scholar 

  35. Holmback K, et al. Impaired platelet aggregation and sustained bleeding in mice lacking the fibrinogen motif bound by integrin alpha IIb beta 3. EMBO J 1996;15:5760–5771.

    PubMed  CAS  Google Scholar 

  36. Litvinov RI, et al. Binding strength and activation state of single fibrinogen-integrin pairs on living cells. Proc Natl Acad Sci USA 2002;99:7426–7431.

    Article  PubMed  CAS  Google Scholar 

  37. Rooney MM, Parise LV, Lord ST. Dissecting clot retraction and platelet aggregation. Clot retraction does not require an intact fibrinogen gamma chain C terminus. J Biol Chem 1996;271:8553–8555.

    Article  PubMed  CAS  Google Scholar 

  38. Gawaz MP, et al. Ligand bridging mediates integrin alpha IIb beta 3 (platelet GPIIB- IIIA) dependent homotypic and heterotypic cell-cell interactions. J Clin Invest 1991;88:1128–1134.

    Article  PubMed  CAS  Google Scholar 

  39. Weber C, Springer T. Neutrophil accumulation on activated, surface-adherent platelets in flow is mediated by interaction of Mac-1 with fibrinogen bound to aIIbb3 and stimulated by platelet-activating factor. J Clin Invest 1997;100:2085–2093.

    Article  PubMed  CAS  Google Scholar 

  40. Montgomery R, Coller B von Willebrand disease. In: Colman R, et al., eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. JB Lippincott, Philadelphia, 1994, pp. 134–168.

    Google Scholar 

  41. Yuan Y, et al. Calpain regulation of cytoskeletal signaling complexes in von Willebrand factor-stimulated platelets. Distinct roles for glycoprotein Ib-V-Ix and glycoprotein IIb-IIIa (integrin alphaIIb beta3) in von Willebrand factor-induced signal transduction [In Process Citation]. J Biol Chem 1997;272: 21,847–21,854.

    CAS  Google Scholar 

  42. Savage B, Saldivar E, Ruggeri Z. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell 1996;84:289–297.

    Article  PubMed  CAS  Google Scholar 

  43. Chow TW, et al. Shear stress-induced von Willebrand factor binding to platelet glycoprotein Ib initiates calcium influx associated with aggregation. Blood 1992;80:113–120.

    PubMed  CAS  Google Scholar 

  44. Goto S, et al. Distinct mechanisms of platelet aggregation as a consequence of different shearing flow conditions. J Clin Invest 1998;101:479–486.

    Article  PubMed  CAS  Google Scholar 

  45. Lefkovits J, Topol EJ. The clinical role of platelet glycoprotein IIb/IIIa receptor inhibitors in ischemic heart disease. Cleve Clin J Med 1996;63:181–189.

    PubMed  CAS  Google Scholar 

  46. Coller BS. Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics. J Clin Invest 1997; 100(11 Suppl):S57–S60.

    PubMed  CAS  Google Scholar 

  47. Scarborough RM, et al. Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri. J Biol Chem 1991;266:9359–9362.

    PubMed  CAS  Google Scholar 

  48. Niewiarowski S, et al. Disintegrins and other naturally occurring antagonists of platelet fibrinogen receptors. Semin Hematol 1994;31:289–300.

    PubMed  CAS  Google Scholar 

  49. Scarborough RM, et al. Characterization of the integrin specificities of disintegrins isolated from American pit viper venoms. J Biol Chem 1993;268:1058–1065.

    PubMed  CAS  Google Scholar 

  50. Scarborough RM, et al. Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa. J Biol Chem 1993;268:1066–1073.

    PubMed  CAS  Google Scholar 

  51. Phillips DR, Scarborough RM. Clinical pharmacology of eptifibatide. Am J Cardiol 1997;80:11B–20B.

    Article  PubMed  CAS  Google Scholar 

  52. Hartman GD, et al. Non-peptide fibrinogen rcceptor antagonists. 1. Discovery and design of exosite inhibitors. J Med Chem 1992;35:4640–4642.

    Article  PubMed  CAS  Google Scholar 

  53. Zablocki JA, et al. Potent inhibitors of platelet aggregation based upon the Arg-Gly-Asp-Phe sequence of fibrinogen. A proposal on the nature of the binding interaction between the Asp-carboxylate of RGDX mimetics and the platelet GP IIb-IIIa receptor. J Med Chem 1992;35:4914–4917.

    Article  PubMed  CAS  Google Scholar 

  54. Mayo KH, et al. RGD induces conformational transition in purified platelet integrin GPIIb/IIIa-SDS systern yielding multiple binding states for fibrinogen gamma-chain C-terminal peptide. FEBS Lett 1996; 378:79–82.

    Article  PubMed  CAS  Google Scholar 

  55. Rivas GA, Gonzalez-Rodriguez J. Calcium binding to human platelet integrin GPIIb/IIIa and to its constituent glycoproteins. Effects of lipids and temperature. Biochem J 1991;276:35–40.

    PubMed  CAS  Google Scholar 

  56. Ciemiewski CS, et al. Characterization of cation-binding sequences in the platelet integrin GPIIb-IIIa (alpha lIb beta 3) by terbium luminescence. Biochemistry 1994;33:12,238–12,246.

    Google Scholar 

  57. Marguerie GA, Edgington TS, Plow EF. Interaction of fibrinogen with its platelet receptor as part of a multistep reaction in ADP-induced platelet aggregation. J Biol Chem 1980;255:154–161.

    PubMed  CAS  Google Scholar 

  58. Fitzgerald LA, Phillips DR. Calcium regulation of the platelet membrane glycoprotein IIb-IIIa complex. J Biol Chem 1985;260:11,366–11,374.

    CAS  Google Scholar 

  59. Fujimura K, Phillips DR. Calcium cation regulation of glycoprotein IIb-IIIa complex formation in platelet plasma membranes. J Biol Chem 1983;258:10,247–10,252.

    CAS  Google Scholar 

  60. Hu DD, Barbas CF, Smith JW. An allosteric Ca2+ binding site on the beta3-integrins that regulates the dissociation rate for RGD ligands. J Biol Chem 1996;271:21,745–21,751.

    CAS  Google Scholar 

  61. Phillips DR, et al. Effect of Ca2+ on GP IIb-IIIa interactions with Integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation 1997;96:1488–1494.

    Article  PubMed  CAS  Google Scholar 

  62. Marciniak SJ Jr, Jordan RE, Mascelli MA. Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban. Thromb Haemost 2001;85:539–543.

    PubMed  CAS  Google Scholar 

  63. Kouns WC, et al. A conformation-dependent epitope of human platelet glycoprotein IIIa. J Biol Chem 1990;265:20,594–20,601.

    CAS  Google Scholar 

  64. Frelinger AL III, et al. Selective inhibition of integrin function by antibodies specific for ligand-occupied receptor conformers. J Biol Chem 1990;265:6346–6352.

    PubMed  CAS  Google Scholar 

  65. Xiong JP, et al. Crystal structure of the extracellular segment of integrin alpha Vbeta3. Science 2001; 294:339–345.

    Article  PubMed  CAS  Google Scholar 

  66. Abraham DG, et al. Arginine-glycine-aspartic acid mimics can identify a transitional activation state of recombinant alphaIIb beta3 in human embryonic kidney 293 cells. Mol Pharmacol 1997;52:227–236.

    PubMed  CAS  Google Scholar 

  67. Dickfeld T, et al. Differential antiplatelet effects of various glycoprotein IIb-IIIa antagonists. Thromb Res 2001;101:53–64.

    Article  PubMed  CAS  Google Scholar 

  68. Jennings LK, Haga JH, Slack SM. Differential expression of a ligand induced binding site (LIBS) by GPIIb-IIIa ligand recognition peptides and parenteral antagonists. Thromb Haemost 2000;84: 1095–1102.

    PubMed  CAS  Google Scholar 

  69. Ferrari E, et al. Acute profound thrombocytopenia after c7E3 Fab therapy. Circulation 1997;96: 3809–3810.

    PubMed  CAS  Google Scholar 

  70. Simpfendorfer C, et al. First chronic platelet glycoprotein IIb/IIIa integrin blockade. A randomized, placebo-controlled pilot study of Xemlifoban in unstable angina with percutaneous coronary interventions. Circulation 1997;96:76–81.

    Article  PubMed  CAS  Google Scholar 

  71. Cannon C, et al. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome. Circulation 1998;97:340–349.

    Article  PubMed  CAS  Google Scholar 

  72. Vorchheimer DA, Fuster V. Oral platelet glycoprotein receptor antagonists: the present challenge is safety. Circulation 1998;97:312–314.

    Article  PubMed  CAS  Google Scholar 

  73. Bednar B, et al. Fibrinogen receptor antagonist-induced thrombocytopenia in chimpanzee and rhesus monkey associated with preexisting drug-dependent antibodies to platelet glycoprotein IIb/IIIa. Blood 1999;94:587–599.

    PubMed  CAS  Google Scholar 

  74. Billheimer JT, et al. Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated. Blood 2002;99:3540–3546.

    Article  PubMed  CAS  Google Scholar 

  75. Berkowitz SD, et al. Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. Circulation 1997;95:809–813.

    Article  PubMed  CAS  Google Scholar 

  76. Bougie DW, Robbins ED, Aster RH. Antibodies associated with tirofiban-induced thrombocytopenia recognize multiple sites on ligand-occupied GPIIB/IIIA and may be specific for ligand-induced binding sites (LIBS). Blood 2001;98:1861.

    Google Scholar 

  77. Shattil S, Kashiwagi H, Pampori N. Integrin signaling: the platelet paradigm. Blood 1998;91:1–14.

    Google Scholar 

  78. Shattil SJ, Ginsberg MH, Brugge JS. Adhesive signaling in platelets. Curr Opin Cell Biol 1994;6: 695–704.

    Article  PubMed  CAS  Google Scholar 

  79. Hollopeter G, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001:409:202–207.

    Article  PubMed  CAS  Google Scholar 

  80. Daniel J, et al. Molecular basis for ADP-induced platelet activation. I. Evidence for three distint ADP receptors on human platelets. J Biol Chem 1998;273:2024–2029.

    Article  PubMed  CAS  Google Scholar 

  81. Mills DCB. ADP receptors on platelets. Thromb Haemost 1996;76:835–856.

    PubMed  CAS  Google Scholar 

  82. Kahmann RD, et al. Platelet function in adolescent idiopathic scoliosis. Spine 1992;17:145–148.

    Article  PubMed  CAS  Google Scholar 

  83. Keely PJ, Parise LV. The alpha2betal integrin is a necessary co-receptor for collagen-induced activation of Syk and the subsequent phosphorylation of phospholipase Cgamma2 in platelets. J Biol Chem 1996;271:26,668–26,676.

    Article  CAS  Google Scholar 

  84. Ishibashi T, et al. Functional significance of platelet membrane glycoprotein p62 (GP VI), a putative collagen receptor. Int J Hematol 1995;62:107–111.

    Article  PubMed  CAS  Google Scholar 

  85. Sugiyama T, et al. A novel platelet aggregating factor found in a patient with defective collageninduced platelet aggregation and autoimmune thrombocytopenia. Blood 1987;69:1712–1720.

    PubMed  CAS  Google Scholar 

  86. Coller BS, et al. Collagen-platelet interactions: evidence for a direct interaction of collagen with platelet GPIIb/IIIa and an indirect interaction with platelet GPIIb/IIIa mediated by adhesive proteins. Blood 1989;74:182–192.

    PubMed  CAS  Google Scholar 

  87. Handa M, et al. Platelet unresponsiveness to collagen: involvement of glycoprotein la-lIa (alpha 2 beta 1 integrin) deficiency associated with a myeloproliferative disorder. Thromb Haemost 1995;73:521–528.

    PubMed  CAS  Google Scholar 

  88. Arai M, et al. Platelets with 10% of the normal amount of glycoprotein VI have an impaired response to collagen that results in a mild bleeding tendency. Br J Haematol 1995;89:124–130.

    Article  PubMed  CAS  Google Scholar 

  89. Ichinohe T, et al. Collagen-stimulated activation of Syk but not c-Src is severely compromised in human platelets lacking membrane glycoprotein VI. J Biol Chem 1997;272:63–68.

    Article  PubMed  CAS  Google Scholar 

  90. Vu TK, et al. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991;64:1057–1068.

    Article  PubMed  CAS  Google Scholar 

  91. Cook JJ, et al. An antibody against the exosite of the cloned thrombin receptor inhibits experimental arterial thrombosis in the African green monkey. Circulation 1995;91:2961–2971.

    Article  PubMed  CAS  Google Scholar 

  92. Henriksen RA, Samokhin, Tracy PB. Thrombin-induced thromboxane synthesis by human platelets. Properties of anion binding exosite I-independent receptor. Arterioscler Thromb Vasc Biol 1997;17: 3519–3526.

    Article  PubMed  CAS  Google Scholar 

  93. Clemetson KJ. Platelet activation: signal transduction via membrane receptors. Thromb Haemost 1995; 74:111–116.

    PubMed  CAS  Google Scholar 

  94. Andrews R, et al. Binding of the purified 14–3–3z signaling protein to discrete amino acid sequences within the cytoplasmic domian of the platelet membrane glycoprotein Ib-IX-V complex. Biochemistry 1998;37:638–647.

    Article  PubMed  CAS  Google Scholar 

  95. Yap CL, et al. Essential role for phosphoinositide 3-kinase in shear-dependent signaling between platelet glycoprotein Ib/V/IX and integrin alpha(IIb)beta(3). Blood 2002;99:151–158.

    Article  PubMed  CAS  Google Scholar 

  96. Ramakrishnan V, et al. Increased thrombin responsiveness in platelets from mice lacking glycoprotein V. Proc Natl Acad Sci USA 1999;96:13,336–13,341.

    Article  CAS  Google Scholar 

  97. Ramakrishnan V, et al. A thrombin receptor function for platelet glycoprotein Ib-IX unmasked by cleavage of glycoprotein V. Proc Natl Acad Sci USA 2001;98:1823–1828.

    Article  PubMed  CAS  Google Scholar 

  98. Neer E. Heterotrimeric G proteins: organizers of transmembrane signals. Cell, 1995;80:249–257.

    Article  PubMed  CAS  Google Scholar 

  99. Offermanns S, et al. Defective platelet activation in G alpha(q)-deficient mice. Nature 1997;389:183–186.

    Article  PubMed  CAS  Google Scholar 

  100. Gabbeta J, et al. Platelet signal transduction defect with Ga subunit dysfunction and diminished Gaq in a patient with abnormal platelet responses. Proc Natl Acad Sci USA 1997;94:8750–8755.

    Article  PubMed  CAS  Google Scholar 

  101. Jantzen HM, et al. Impaired activation of murine platelets lacking G alpha(i2). J Clin Invest 2001;108: 477–483.

    PubMed  CAS  Google Scholar 

  102. Tsuji M, et al. A novel association of Fc receptor gamma-chain with glycoprotein VI and their coexpression as a collagen receptor in human platelets In Process Citation]. J Biol Chem, 1997;272: 23,528–23,531.

    Article  CAS  Google Scholar 

  103. Poole A, et al. The Fc receptor gamma-chain and the tyrosine kinase Syk are essential for activation of mouse platelets by collagen. EMBU J 1997;16:2333–2341.

    Article  CAS  Google Scholar 

  104. Suzuki-Inoue K, et al. Association of Fyn and Lyn with the proline rich domain of GPVI regulates intracellular signalling. J Biol Chem 2002;277:21,561–21,566.

    Article  CAS  Google Scholar 

  105. Falati S, Edmead CE, Poole AW. Glycoprotein Ib-V-IX, a receptor for von Willebrand factor, couples physically and functionally to the FC receptor gamma-chain, Fyn, and Lyn to activate human platelets. Blood 1999;94:1648–1656.

    PubMed  CAS  Google Scholar 

  106. Du X, et al. Association of a phospholipase A2 (14–3–3 protein) with the platelet glycoprotein Ib-IX complex. J Biol Chem 1994;269:18,287–18,290.

    CAS  Google Scholar 

  107. Calverley D, Kavanagh T, Roth G. Human signaling protein 14–3–3z interacts with platelet glycoprotein Ib subunits Iba and Ibb. Blood 1998;91:1295–1303.

    PubMed  CAS  Google Scholar 

  108. Dubois T, et al. Structure and sites of phosphorylationof 14–3–3 protein: role in coordinating signal transduction pathways. J Protein Chem 1997;16:513–522.

    Article  PubMed  CAS  Google Scholar 

  109. Schoenwaelder SM, et al. RhoA sustains integrin alpha IIbbeta 3 adhesion contacts under high shear. J Biol Chem 2002;277:14,738–14,746.

    CAS  Google Scholar 

  110. Zaffran Y, et al. Signaling across the platelet adhesion receptor glycoprotein Ib-IX induces alpha IIbbeta 3 activation both in platelets and a transfected Chinese hamster ovary cell system. J Biol Chem 2000; 275:16,779–16,787.

    Article  CAS  Google Scholar 

  111. Missiaen L, Taylor CW, Berridge MJ. Spontaneous calcium release from inositol trisphosphate-sensitive calcium stores. Nature 1991;352:241–244.

    Article  PubMed  CAS  Google Scholar 

  112. Lages B, Weiss H. Evidence for a role of glycoprotein IIIb-IIIa, distinct from its ability to support aggregation, in platelet activation by ionophores in the presence of extracellular divalent cations. Blood 1994; 83:2549–2559.

    PubMed  CAS  Google Scholar 

  113. Puri R, Colman R. Thrombin- and cathepsin G-induced platelet aggregation: effect of protein kinase C inhibitors. Anal Biochem 1993;210:50–57.

    Article  PubMed  CAS  Google Scholar 

  114. Mustard JF, Kinlough-Rathbone RL, Packham MA. Aspirin in the treatment of cardiovascular disease: a review. Am J Med 1983;74:43–49.

    Article  PubMed  CAS  Google Scholar 

  115. Shattil SJ, et al. Beta 3-endonexin, a novel polypeptide that interacts specifically with the cytoplasmic tail of the integrin beta 3 subunit. J Cell Biol 1995;131:807–816.

    Article  PubMed  CAS  Google Scholar 

  116. Naik UP, Patel PM, Parise LV. Identification of a novel calcium-binding protein that interacts with the integrin alphaIIb cytoplasmic domain. J Biol Chem 1997;272:4651–4654.

    Article  PubMed  CAS  Google Scholar 

  117. Barry WT, et al. Molecular basis of CIB binding to the integrin alphaIIb cytoplasmic domain. J Biol Chem 2002;277:28,877–28,883.

    CAS  Google Scholar 

  118. Tsuboi S. Calcium integrin-binding protein activates platelet integrin alpha IIbbeta 3. J Biol Chem 2002; 277:1919–1923.

    Article  PubMed  CAS  Google Scholar 

  119. Vallar L, et al. Divalent cations differentially regulate integrin alphaIIb cytoplasmic tail binding to beta3 and to calcium- and integrin-binding protein. J Biol Chem 1999;274:17,257–17,266.

    Article  CAS  Google Scholar 

  120. Brisson C, et al. Co-localization of CD9 and GPIIb-IIIa (alpha IIb beta 3 integrin) on activated platelet pseudopods and alpha-granule membranes. Histochem J 1997;29:153–165.

    Article  PubMed  CAS  Google Scholar 

  121. Indig FE, Diaz-Gonzalez F, Ginsberg MH. Analysis of the tetraspanin CD9-integrin alphaIIbbeta3 (GPIIb-IIIa) complex in platelet membranes and transfected cells. Biochem J 1997;327:291–298.

    PubMed  CAS  Google Scholar 

  122. Chung J, Gao AG, Frazier WA. Thrombspondin acts via integrin-associated protein to activate the platelet integrin alphaIIbbeta3. J Biol Chem 1997;272:14,740–14,746.

    CAS  Google Scholar 

  123. Fenczik CA, Sethi T, Ramos JW, Hughes PE, Ginsberg MH. Complementation of dominant supression implicates CD98 in integrin activation. Nature 1997;390:81–85.

    Article  PubMed  CAS  Google Scholar 

  124. Fitter S, et al. Transmembrane 4 superfamily protein CD151 (PETA-3) associates with beta 1 and alpha IIb beta 3 integrins in haemopoietic cell lines and modulates cell-cell adhesion. Biochem J 1999;338:61–70.

    Article  PubMed  CAS  Google Scholar 

  125. Sims PJ, et al. Effect of platelet activation on the conformation of the plasma membrane glycoprotein IIb-IIIa complex. J Biol Chem 1991;266:7345–7352.

    PubMed  CAS  Google Scholar 

  126. Kieffer N, et al. Adhesive properties of the beta 3 integrins: comparison of GP IIb-IIIa and the vitronectin receptor individually expressed in human melanoma cells. J Cell Biol 1991;113:451–461.

    Article  PubMed  CAS  Google Scholar 

  127. Uthoff K, et al. Inhibition of platelet adhesion during cardiopulmonary bypass reduces postoperative bleeding. Circulation 1994;90:11269–11274.

    Google Scholar 

  128. Carroll R, et al. Blocking platelet aggregation inhibits thromboxane A2 formation by low dose agonists but does not inhibit phosphorylation and activation of cytosolic phospholipase A2. Thromb Res 1997; 88:109–125.

    Article  PubMed  CAS  Google Scholar 

  129. Tsao P, Forsythe M, Mousa S. Dissociation between the anti-aggregatory and anti-secretory effects of platelet integrin aIIbb3 (GPIIb/IIIa) antagonists, c7E3 and DMP728. Thromb Res 1997;88:137–146.

    Article  PubMed  CAS  Google Scholar 

  130. Marcus A, etal. The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39. J Clin Invest 1997;99:1351–1360.

    Article  PubMed  CAS  Google Scholar 

  131. Esmon N, Carroll R, Esmon C. Thrombomodulin blocks the ability of thrombin to activate platelets. J Biol Chem 1983;258:12,238–12,242.

    CAS  Google Scholar 

  132. Enjyoji K, et al. Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Nat Med 1999;5:1010–1017.

    Article  PubMed  CAS  Google Scholar 

  133. Law DA, Nannizzi-Alaimo L, Phillips DR. Outside-in integrin signal transduction. Alpha IIb beta 3-(GP IIb Ma) tyrosine phosphorylation induced by platelet aggregation. J Biol Chem 1996;271: 10,811–10,815.

    CAS  Google Scholar 

  134. Law DA, et al. Integrin cytoplasmic tyrosine motif is required for outside-in alphaIIbbeta3 signalling and platelet function. Nature 1999;401:808–811.

    Article  PubMed  CAS  Google Scholar 

  135. Phillips DR, Nannizzi-Alaimo L, Prasad KS. Beta3 tyrosine phosphorylation in alphaIIbbeta3 (platelet membrane GP IIb-IIIa) outside-in integrin signaling. Thromb Haemost 2001;86:246–258.

    PubMed  CAS  Google Scholar 

  136. Cowan KJ, Law DA, Phillips DR. Identification of shc as the primary protein binding to the tyrosinephosphorylated beta 3 subunit of alpha IIbbeta 3 during outside-in integrin platelet signaling. J Biol Chem 2000;275:36,423–36,429.

    PubMed  CAS  Google Scholar 

  137. Shattil SJ, Brugge JS. Protein tyrosine phosphorylation and the adhesive functions of platelets. Curr Onin Cell Riol 1991:3:869–879.

    Article  CAS  Google Scholar 

  138. Clark EA, Shattil SJ, Brugge JS. Regulation of protein tyrosine kinases in platelets. Trends Biochem Sei 1994:19:464–469.

    Article  CAS  Google Scholar 

  139. Dillon AMR, Heath MF. The effects of tyrophostins B42 and B46 on equine platelet function and protein tyrosine phosphorvlation. Biochem Biophy Res Commun 1995;212:595–601.

    Article  CAS  Google Scholar 

  140. Salari H, et al. Erbstatin blocks platelet activating factor-induced protein-tyrosine phosphorylation, polyphosphoinositide hydrolysis, protein kinase C activation, serotonin secretion and aggregation of rabbit platelets. FEBS 1990;263:104–108.

    Article  CAS  Google Scholar 

  141. Hargreaves PG, et al. The tyrosine kinase inhibitors, genistein, and methyl 2,5-dihydroxycinnamate, inhibit the release of (3H)arachidonate from human platelets stimulated by thrombin or collagen. Thromb Haemost 1994;72:634–642.

    PubMed  CAS  Google Scholar 

  142. Obergfell A, et al. Coordinate interactions of Csk, Src, and Syk kinases with [alpha] IIb[betal 3 initiate integrin signaling to the cytoskeleton. J Cell Biol 2002;157:265–275.

    Article  PubMed  CAS  Google Scholar 

  143. Dorahy DJ, Berndt MC, Burns GF. Capture by chemical crosslinkers provides evidence that integrin alpha IIb beta 3 forms a complex with protein tyrosine kinases in intact platelets. Biochem J 1995;309: 481–490.

    PubMed  CAS  Google Scholar 

  144. Soriano P, et al. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 1991;64:693–702.

    Article  PubMed  CAS  Google Scholar 

  145. Cho MJ, et al. Role of the Src family kinase Lyn in TxA2 production, adenosine diphosphate secretion, Akt phosphorylation, and irreversible aggregation in platelets stimulated with gamma-thrombin. Blood 2002;99:2442–2447.

    Article  PubMed  CAS  Google Scholar 

  146. Shattil SJ, et al. Tyrosine phosphorylation of pp125FAK in platelets requires coordinated signaling through integrin and agonist receptors. J Biol Chem 1994;269:14,738–14,745.

    PubMed  CAS  Google Scholar 

  147. Eide BL, Turck CW, Escobedo JA. Identification of Tyr-397 as the primary site of tyrosine phosphorylation and pp60src association in the focal adhesion kinase, pp125FAK. Mol Cell Biol 1995;15: 2819–2827.

    PubMed  CAS  Google Scholar 

  148. Zhang J, et al. Phosphoinositide 3-kinase gamma and p85/phosphoinositide 3-kinase in platelets. Relative activation by thrombin receptor or beta-phorbol myristate acetate and roles in promoting the ligand-binding function of alphaIIbbeta3 integrin. J Biol Chem 1996;271:6265–6272.

    Article  PubMed  CAS  Google Scholar 

  149. Hartwig JH, et al. D3 phosphoinositides and outside-in integrin signaling by glycoprotein IIb-IIIa mediate platelet actin assembly and filopodial extension induced by phorbol 12-myristate 13-acetate. J Biol Chem 1996;271:32,986–32,993.

    Article  CAS  Google Scholar 

  150. Guinebault C, et al. Integrin-dependent translocation of phosphoinositide 3-kinase to the cytoskeleton of thrombin-activated platelets involves specific interactions of p85 alpha with actin filaments and focal adhesion kinase. J Cell Biol 1995;129:831–842.

    Article  PubMed  CAS  Google Scholar 

  151. Kovacsovics TJ, et al. Phosphoinositide 3-kinase inhibition spares actin assembly in activating platelets but reverses platelet aggregation. J Biol Chem 1995;270:11,358–11,366.

    Article  CAS  Google Scholar 

  152. Hirsch E, et al. Resistance to thromboembolism in PI3Kgamma-deficient mice. FASEB J 2001;15: 2019–2021.

    PubMed  CAS  Google Scholar 

  153. Giuriato S, et al. Tyrosine phosphorylation and relocation of SHIP are integrin-mediated in thrombinstimulated human blood platelets. J Biol Chem 1997;272:26,857–26,863.

    Article  CAS  Google Scholar 

  154. Fox JE. On the role of calpain and Rho proteins in regulating integrin-induced signaling. Thromb Haemost 1999;82:385–391.

    PubMed  CAS  Google Scholar 

  155. Fox JE. Cytoskeletal proteins and platelet signaling. Thromb Haemost 2001;86:198–213.

    PubMed  CAS  Google Scholar 

  156. Du X, et al. Calpain cleavage of the cytoplasmic domain of the integrin beta 3 subunit. J Biol Chem 1995;270:26,146–26,151.

    Article  CAS  Google Scholar 

  157. Azam M, et al. Disruption of the mouse mu-calpain gene reveals an essential role in platelet function. Mol Cell Biol 2001;21:2213–2220.

    Article  PubMed  CAS  Google Scholar 

  158. Schoenwaelder SM, et al. Calpain cleavage of focal adhesion proteins regulates the cytoskeletal attachment of integrin alphaIIbbeta3 (platelet glycoprotein IIb/IIIa) and the cellular retraction of fibrin clots. J Biol Chem 1997;272:1694–1702.

    Article  PubMed  CAS  Google Scholar 

  159. Dash D, Aepfelbacher M, Siess W. Integrin alpha IIb beta 3-mediated translocation of CDC42Hs to the cytoskeleton in stimulated human platelets. J Biol Chem 1995;270:17,321–17,326.

    CAS  Google Scholar 

  160. Tapon N, Hall A. Rho, Rac and Cdc42 GTPases regulate the organization of the actin cytoskeleton. Curr Opin Cell Biol 1997;9:86–92.

    Article  PubMed  CAS  Google Scholar 

  161. Dedhar S, Hannigan GE. Integrin cytoplasmic interactions and bidirectional transmembrane signalling. Curr Opin Cell Biol 1996;8:657–669.

    Article  PubMed  CAS  Google Scholar 

  162. Phillips DR, Jennings LK, Edwards HH. Identification of membrane proteins mediating the interaction of human platelets. J Cell Biol 1980;86:77–86.

    Article  PubMed  CAS  Google Scholar 

  163. Fox JE, et al. On the role of the platelet membrane skeleton in mediating signal transduction. Association of GP IIb-IIIa, pp60c-src, pp62c-yes, and the p2 1 ras GTPase-activating protein with the membrane skeleton. J Biol Chem 1993;268:25,973–25,984.

    CAS  Google Scholar 

  164. Nannizzi-Alaimo L, Jenkins AL, Law DA, Eigenthaler M, Ginsberg MH, Phillips DR. The tyrosine residues within b3 are phosphorylated only upon platelet aggregation and are required for b3-dependent clot retraction in CHO cells. Blood 1997;90(Suppl):426a (abstract 1892).

    Google Scholar 

  165. Jenkins AL, et al. Tyrosine phosphorylation of the beta3 cytoplasmic domain mediates integrin-cytoskeletal interactions. J Biol Chem 1998;273:13,878–13,885.

    CAS  Google Scholar 

  166. Simmons SR, Albrecht RM. Self-association of bound fibrinogen on platelet surfaces. J Lab Clin Med 1997;128:39–50.

    Article  Google Scholar 

  167. Coller BS, et al. Studies of activated GPIIb/IIIa receptors on the luminal surface of adherent platelets. Paradoxical loss of luminal receptors when platelets adhere to high density fibrinogen. J Clin Invest 1993;92:2796–2806.

    Article  PubMed  CAS  Google Scholar 

  168. Knezevic I, Leisner TM, Lam SC. Direct binding of the platelet integrin alphaIIbbeta3 (GPIIb-IIIa) to talin. Evidence that interaction is mediated through the cytoplasmic domains of both alphaIIb and beta3. J Biol Chem 1996;271:16,416–16,421.

    CAS  Google Scholar 

  169. Otey CA, Pavalko FM, Burridge K. An interaction between alpha-actinin and the beta 1 integrin subunit in vitro. J Cell Biol 1990;111:721–729.

    Article  PubMed  CAS  Google Scholar 

  170. Reddy KB, et al. Identification and characterization of a specific interaction between skelemin and beta integrin cytoplasmic tails. Circulation Suppl I 1996;94:1–98.

    Google Scholar 

  171. Chen YP, et al. A point mutation in the integrin beta 3 cytoplasmic domain (5752->P) impairs bidirectional signaling through alpha lIb beta 3 (platelet glycoprotein IIb-IIIa). Blood 1994;84:1857–1865.

    PubMed  CAS  Google Scholar 

  172. Blystone SD, et al. Requirement of integrin beta3 tyrosine 747 for beta3 tyrosine phosphorylation and regulation of alphavbeta3 avidity. J Biol Chem 1997;272:28,757–28,761.

    Article  CAS  Google Scholar 

  173. Schoenwaelder SM, et al. Tyrosine kinases regulate the cytoskeletal attachment of integrin alpha IIb beta 3 (platelet glycoprotein IIb/IIIa) and the cellular retraction of fibrin polymers. J Biol Chem 1994; 269:32,479–32,487.

    CAS  Google Scholar 

  174. French DL. Glanzmann Thrombasthenia Database. 1999.

    Google Scholar 

  175. Djaffar I, Rosa JP. A second case of variant of Glanzmann’s thrombasthenia due to substitution of platelet GPIIIa (integrin beta 3) Arg214 by Trp. Hum Mol Genet 1993;2:2179–2180.

    Article  PubMed  CAS  Google Scholar 

  176. Kato A, et al. Molecular basis for Glanzmann’s thrombasthenia (GT) in a compound heterozygote with glycoprotein IIb gene: a proposal for the classification of GT based on the biosynthetic pathway of glycoprotein IIb-IIIa complex. Blood 1992;79:3212–3218.

    PubMed  CAS  Google Scholar 

  177. Djaffar I, Caen JP, Rosa JP. A large alteration in the human platelet glycoprotein IIIa (integrin beta 3) gene associated with Glanzmann’s thrombasthenia. Hum Mol Genet 1993;2:2183–2185.

    Article  PubMed  CAS  Google Scholar 

  178. Chen YP, et al. Ser-752→Pro mutation in the cytoplasmic domain of integrin beta 3 subunit and defective activation of platelet integrin alpha IIb beta 3 (glycoprotein lIb-IIIa) in avariant of Glanzmann thrombasthenia. Proc Natl Acad Sci USA 1992;89:10,169–10,173.

    CAS  Google Scholar 

  179. Newman P, Derbes R, Aster R. The human platelet alloantigens, PlAl and P1A2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing. J Clin Invest 1989;83:1778–1781.

    Article  PubMed  CAS  Google Scholar 

  180. Weiss EJ, et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996;334:1090–1094.

    Article  PubMed  CAS  Google Scholar 

  181. Walter DH, et al. Platelet glycoprotein IIIa polymorphisms and risk of coronary stent thrombosis. Lancet 1997;350:1217–1219.

    Article  PubMed  CAS  Google Scholar 

  182. Carter A, et al. Association of the platelet PlA polymorphism of glycoprotein IIb/IIIa and the fibrinogen Bb 448 polymorphism with myocardial infarction and extent of coronary disease. Circulation 1997; 96:1424–1431.

    Article  PubMed  CAS  Google Scholar 

  183. Herrmann SM, et al. The Leu33/Pro polymorphism (PIA 1/P1A2) of the glycoprotein Ina (GPIIIa) receptor is not related to myocardial infarction in the ECTIM Study. Etude Cas-Témoins de l’Infarctus du Myocarde. Thromb Haemost 1997;77:1179–1181.

    PubMed  CAS  Google Scholar 

  184. Samani NJ, Lodwick D. Glycoprotein IIIa polymorphism and risk of myocardial infarction. Cardiovasc Res 1997;33:693–697.

    Article  PubMed  CAS  Google Scholar 

  185. Bennett JS, et al. Effect of the Pl(A2) alloantigen on the function of beta(3)-integrins in platelets. Blood 2001;97:3093–3099.

    Article  PubMed  CAS  Google Scholar 

  186. Murata M, et al. Coronary artery disease and polymorphisms in a receptor mediating shear stress-dependent platelet activation. Circulation 1997;96:3281–3286.

    Article  PubMed  CAS  Google Scholar 

  187. de Maat MP, et al. PIA 1 /A2 polymorphism of platelet glycoprotein IIIa and risk of cardiovascular disease. Lancet 1997;349:1099–1100.

    Article  PubMed  Google Scholar 

  188. Feng D, et al. Increased platelet aggregablilty associated with platelet GPIIIa PLA2 polymorphism. Circulation 1997;96a:I-412 (abstract 2301).

    Google Scholar 

  189. Vijayan KV, et al. The Pl(A2) polymorphism of integrin beta(3) enhances outside-in signaling and adhesive functions. J Clin Invest 2000;105:793–802.

    Article  PubMed  CAS  Google Scholar 

  190. Wheeler GL, et al. Reduced inhibition by abciximab in platelets with the P1A2 polymorphism. Am Heart J 2002;143:76–82.

    Article  PubMed  CAS  Google Scholar 

  191. Undas A, et al. Pl(A2) polymorphism of beta(3) integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury. Circulation 2001;104:2666–2672.

    Article  PubMed  CAS  Google Scholar 

  192. O’Connor FF, et al. Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes. Blood 2001; 98:3256–3260.

    Article  PubMed  Google Scholar 

  193. Graf D, et al. Cloning of TRAP, a ligand for CD40 on human T cells. EurJ Immunol 1992;22:3191–3194.

    Article  CAS  Google Scholar 

  194. Mach F, et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD4O-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci USA 1997;94:1931–1936.

    Article  PubMed  CAS  Google Scholar 

  195. Hollenbaugh D, et al. Expression of functional CD40 by vascular endothelial cells. J Exp Med 1995; 182:33–40.

    Article  PubMed  CAS  Google Scholar 

  196. Slupsky JR, et al. Activated platelets induce tissue factor expression on human umbilical vein endothelial cells by ligation of CD40. Thromb Haemost 1998;80:1008–1014.

    PubMed  CAS  Google Scholar 

  197. Mach F, et al. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 1998;394: 200–203.

    Article  PubMed  CAS  Google Scholar 

  198. Viallard JF, et al. Increased soluble and platelet-associated CD40 ligand in essential thrombocythemia and reactive thrombocytosis. Blood 2002;99:2612–2614.

    Article  PubMed  CAS  Google Scholar 

  199. Henn V, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998;391:591–594.

    Article  PubMed  CAS  Google Scholar 

  200. Henn V, et al. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood 2001;98:1047–1054.

    Article  PubMed  CAS  Google Scholar 

  201. Aukrust P, et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 1999;100:614–620.

    Article  PubMed  CAS  Google Scholar 

  202. Kiener PA, et al. Stimulation of CD40 with purified soluble gp39 induces proinflammatory responses in human monocytes. J Immunol 1995;155:4917–4925.

    PubMed  CAS  Google Scholar 

  203. Zhang Y, et al. CD40 engagement up-regulates cyclooxygenase-2 expression and prostaglandin E2 production in human lung fibroblasts. J Immunol 1998;160:1053–1057.

    PubMed  CAS  Google Scholar 

  204. Mazzei GJ, et al. Recombinant soluble trimeric CD40 ligand is biologically active. J Biol Chem 1995; 270:7025–7028.

    Article  PubMed  CAS  Google Scholar 

  205. Garlichs CD, et al. Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets. Heart 2001;86:649–655.

    Article  PubMed  CAS  Google Scholar 

  206. Tsakiris DA, et al. Platelets and cytokines in concert with endothelial activation in patients with peripheral arterial occlusive disease. Blood Coagul Fibrinolysis 2000;11:165–173.

    PubMed  CAS  Google Scholar 

  207. Kato K, et al. The soluble CD40 ligand sCD154 in systemic lupus erythematosus. J Clin Invest 1999; 104:947–955.

    Article  PubMed  CAS  Google Scholar 

  208. Schonbeck U, et al. Soluble CD40L and cardiovascular risk in women. Circulation 2001;104:2266–2268.

    Article  PubMed  CAS  Google Scholar 

  209. Nannizzi-Alaimo L, et al. Cardiopulmonary bypass induces release of soluble CD40 ligand. Circulation 2002;105:2849–2854.

    Article  PubMed  CAS  Google Scholar 

  210. Gillis S, Furie B, Furie B. Interactions of neutrophils and coagulation proteins. Semin Hematol 1997;34: 336–342.

    PubMed  CAS  Google Scholar 

  211. Liuzzo G, et al. Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. Circulation 1998;98:2370–2376.

    Article  PubMed  CAS  Google Scholar 

  212. Lincoff AM, et al. Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation 2001;104:163–167.

    Article  PubMed  CAS  Google Scholar 

  213. Merino Otermin A, et al. [Eptifibatide blocks the increase in C-reactive protein concentration after coronary angioplasty]. Rev Esp Cardiol 2002;55:186–189.

    Article  PubMed  Google Scholar 

  214. Reverter JC, et al. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and “clinical restenosis.” J Clin Invest 1996;98:863–874.

    Article  PubMed  CAS  Google Scholar 

  215. Herault J, et al. Effect of SR121566A, a potent GP IIb-IIIa antiagonist on platelet-mediated thrombin generation in vitro and in vivo. Thromb Haemost 1998;79:383–388.

    PubMed  CAS  Google Scholar 

  216. van’t Meer C, et al. Effect of platelet inhibitors on thrombin generation. Blood 1997;90(Suppl):29a (abstract 114).

    Google Scholar 

  217. Molitemo DJ, et al. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial. Am J Cardiol 1995;75:559–562.

    Article  Google Scholar 

  218. Swords N, Tracy P, Mann K. Intact platelet membranes, not platelet-released microvesicles, support the procoagulant activity of adherent platelets. Arterioscler Thromb 1993;13:1613–1622.

    Article  PubMed  CAS  Google Scholar 

  219. Byzova TV, Plow EF. Networking in the hemostatic system. J Biol Chem 1997;272:27,183–27,188.

    Article  CAS  Google Scholar 

  220. Dicker IB, et al. Both the high affinity thrombin receptor (GPIb-IX-V) and GPIIb/IIIa are implicated in expression of thrombin-induced platelet procoagulant activity. Thromb Haemost 2001;86:1065–1069.

    PubMed  CAS  Google Scholar 

  221. Basic-Micic, M, et al. Platelet-induced thrombin generation time: a new sensitive global assay for platelet function and coagulation. Method and first results. Haemostasis 1992;22:309–321.

    PubMed  CAS  Google Scholar 

  222. Mach F, et al. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation 1997;96:396–399.

    Article  PubMed  CAS  Google Scholar 

  223. Andre P, et al. Pro-coagulant state resulting from high levels of soluble P-selectin in blood. Proc Natl Acad Sci USA 2000;97:13,835–13,840.

    CAS  Google Scholar 

  224. Ross R, et al. Localization of PDGF-B protein in macrophages in all phases of atherogenesis. Science 1990248:1009–1012.

    Article  PubMed  CAS  Google Scholar 

  225. Kraiss L, et al. Regional expression of the platelet-derived growth factor and its receptors in a primate graft model of vessel wall assembly. J Clin Invest 1993;92:338–348.

    Article  PubMed  CAS  Google Scholar 

  226. EPILOG Investigators, Platelet glycoprotein GP IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med 1997;336: 1689–1696.

    Article  Google Scholar 

  227. IMPACT-II Investigators. Randomised placebo-controlled trial of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997;349:1422–1428.

    Article  Google Scholar 

  228. RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Circulation 1997;96:1445–1453.

    Article  PubMed  Google Scholar 

  229. Topol EJ, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. Lancet 1994;343: 881–886.

    Article  PubMed  CAS  Google Scholar 

  230. Strauss B, et al. In vivo collagen turnover following experimental balloon angioplasty injury and the role of matrix metalloproteinases. Circ Res 1996;79:541–550.

    Article  PubMed  CAS  Google Scholar 

  231. Bendeck M, et al. Differential expression of al type VIII collagen in injured platelet-derived growth factor-BB-stimulated rat carotid arteries. Circ Res 1996;79:524–531.

    Article  PubMed  CAS  Google Scholar 

  232. Teirstein P. Overview of glycoprotein IIb/IIIa clinical trials with abciximab and eptifibatide in acute coronary syndromes and percutaneous coronary intervention. J Invasive Cardiol 1999;11(Suppl C): 26C–30C.

    PubMed  Google Scholar 

  233. Lee SP, et al. Elevation and biological activity of CD40 ligand (CD40L): potential mechanism of platelet-mediated inflammation in sickle cell disease. Blood 2001;98:2016.

    Google Scholar 

Download references

Authors
  1. Patrick Andre PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David R. Phillips PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, OH, USA

    A. Michael Lincoff MD

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

Andre, P., Phillips, D.R. (2003). Glycoprotein IIb/IIIa in Platelet Aggregation and Acute Arterial Thrombosis. In: Lincoff, A.M. (eds) Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease. Contemporary Cardiology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-376-7_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-376-7_3

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-408-1

  • Online ISBN: 978-1-59259-376-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation